D. Western Therapeutics Institute's (TYO:4576) licensee, Kowa Company, has completed subject dosing in a global Phase III clinical trial for K-321, according to its Tokyo bourse filing on Friday.
K-321 is an ophthalmic solution containing ripasudil hydrochloride hydrate, targeting Fuchs endothelial corneal dystrophy.
The trial, conducted across multiple regions including the U.S. and Europe, evaluates the drug's efficacy and safety post-surgery compared to a placebo, with follow-up observations set to conclude by March 2026.
This milestone follows the earlier completion of another Phase III trial, marking progress toward addressing a condition currently reliant on corneal transplantation.
The development aligns with Kowa's broader strategy to expand ripasudil's applications, though it does not impact the fiscal 2025 earnings forecast.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。